Alzheimer’s disease, a haunting and harrowing ailment, is one of the world’s most common causes of death. Alzheimer’s lingers for years, with patients’ outward appearance unaffected while their cognitive functions fade away. Patients lose the ability to work and live independently, to remember and recognize. There is still no proven way to treat Alzheimer’s because its causes remain unknown. Mind Thief is a comprehensive and engaging history of Alzheimer’s that demystifies efforts to understand the disease. Beginning with the discovery of “presenile dementia” in the early twentieth century, Han Yu examines over a century of research and controversy. She presents the leading hypotheses for what causes Alzheimer’s; discusses each hypothesis’s tangled origins, merits, and gaps; and details their successes and failures. Yu synthesizes a vast amount of medical literature, historical studies, and media interviews, telling the gripping stories of researchers’ struggles while situating science in its historical, social, and cultural contexts. Her chronicling of the trajectory of Alzheimer’s research deftly balances rich scientific detail with attention to the wider implications. In narrating the attempts to find a treatment, Yu also offers a critical account of research and drug development and a consideration of the philosophy of aging. Wide-ranging and accessible, Mind Thief is an important book for all readers interested in the challenge of Alzheimer’s.

Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.

This new volume of Advances in Pharmacology explores the Current State of Alzheimer's Disease Research and Therapeutics. Chapters cover such topics as the The role heat shock proteins play in the Alzheimer's Theater, Gamma-Secretase as a Target for Alzheimer's Disease, and Identification of protein kinase C for the treatment of dementias. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike. - Explores the current state of Alzheimer's disease research and therapeutics - Chapters cover a variety of topics such as the role heat shock proteins play in the Alzheimer's theater, gamma-secretase as a target for Alzheimer's disease, and identification of protein kinase C for the treatment of dementias - With the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike

A definitive and compelling book on one of today's most prevalent illnesses. In 2020, an estimated 5.8 million Americans had Alzheimer’s, and more than half a million died because of the disease and its devastating complications. 16 million caregivers are responsible for paying as much as half of the $226 billion annual costs of their care. As more people live beyond their seventies and eighties, the number of patients will rise to an estimated 13.8 million by 2050. Part case studies, part meditation on the past, present and future of the disease, The Problem of Alzheimer's traces Alzheimer’s from its beginnings to its recognition as a crisis. While it is an unambiguous account of decades of missed opportunities and our health care systems’ failures to take action, it tells the story of the biomedical breakthroughs that may allow Alzheimer’s to finally be prevented and treated by medicine and also presents an argument for how we can live with dementia: the ways patients can reclaim their autonomy and redefine their sense of self, how families can support their loved ones, and the innovative reforms we can make as a society that would give caregivers and patients better quality of life. Rich in science, history, and characters, The Problem of Alzheimer's takes us inside laboratories, patients' homes, caregivers’ support groups, progressive care communities, and Jason Karlawish's own practice at the Penn Memory Center.

Neuroprotection in Alzheimer’s Disease offers a translational point-of-view from both basic and clinical standpoints, putting it on the cusp for further clinical development with its emphasis on nerve cell protection, including the accumulation of knowledge from failed clinical trials and new advances in disease management. This book brings together the latest findings, both basic, and clinical, under the same cover, making it easy for the reader to obtain a complete overview of the state-of-the-field and beyond. Alzheimer's disease is the most common form of dementia, accounting for 60 to 80 percent of dementia cases. It is a progressive brain disease that slowly destroys memory, thinking skills, and eventually, even the ability to carry out the simplest tasks. It is characterized by death of synapses coupled to death nerve cells and brain degeneration which is manifested by loss of cognitive abilities. Understanding neuroprotection in Alzheimer’s disease will pave the path to better disease management and novel therapeutics. Comprehensive reference detailing neuroprotection in Alzheimer’s Disease, with details on nerve cell protection and new advances in disease management Combines the knowledge and points-of-view of both medical doctors and basic scientists, putting the subject at the forefront for further clinical development Edited by one of the leading researchers in Alzheimer’s Disease

In the tradition of Andrew Weil's bestseller Spontaneous Healing, this is a physician's breakthrough medical program for the brain designed to diminish the effect of memory impairment caused by stress, aging, and Alzheimer's disease. As we grow older and experience the stresses of life, at about age 40 many of us begin to have trouble remembering things, concentrating, and generally staying mentally sharp. This book contains a four-part program including nutritional, stress-relieving, pharmacological, and mind-body exercise therapies to help people overcome the undesirable effects of normal brain "aging". By controlling cortisol, a hormone that is toxic to the brain and present in excessive levels as we age, Dr. Khalsa's plan can help improve memory and emotional zest. This is the first book to: Describe a program that may diminish age-associated memory impairment Feature a clinical method that can promote memory functioning impaired by Alzheimer's disease Detail the physical damage done to the brain by stress, how it adversely affects memory and our other mental abilities, and what can be done about it.